Pre-Open Stock Movers 09/01: (ABVC) (PLAN) (BLCM) Higher; (LCID) (NIO) (ASND) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
PVH Corp (PVH) PT Raised to $136 at BofA Securities
September 2, 2021 7:55 AM EDTBofA Securities analyst Lorraine Hutchinson raised the price target on PVH Corp (NYSE: PVH) to $136.00 (from $125.00) while maintaining a Buy rating.
... MoreAscendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh
September 2, 2021 5:23 AM EDTAscendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of $160.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 7, 2021 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to... More
Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint
September 1, 2021 4:32 PM EDTTakeda Pharmaceutical Company Limited (NYSE: TAK) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the... More
Campbell Soup (CPB) PT Lowered to $44 at Stifel
September 1, 2021 3:12 PM EDTStifel analyst Christopher Growe lowered the price target on Campbell Soup (NYSE: CPB) to $44.00 (from $48.00) while maintaining a Hold rating following earnings.
The analyst commented, "Campbell Soup reported 4Q21 EPS of $0.55, representing a 13% decline and standing $0.07 ahead of our estimate. The sales and profit... More
Anaplan Inc. (PLAN) PT Raised to $101 at Monness, Crespi, Hardt
September 1, 2021 10:57 AM EDTMonness, Crespi, Hardt analyst Brian White raised the price target on Anaplan Inc. (NYSE: PLAN) to $101.00 (from $90.00) while maintaining a Buy rating following earnings.
The analyst commented, "Anaplan delivered exceptional 2Q:FY22 results, while issuing strong 3Q:FY22 guidance, and raising... More
